428 Genomic instability metric concordance between oncoscan™, cytosnp and an fda-approved HRD test

Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Matthew J. Marton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gladys Arreaza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ping Qiu(Huzhou Women and Children's Hospital), Andrew Albright(Merck & Co., Inc., Rahway, NJ, USA (United States)), Chen Cai(University of Science and Technology of China), Xiao Qiao Liu(Merck & Co., Inc., Rahway, NJ, USA (United States))
International Journal of Gynecological Cancer
December 1, 2020
Cited by 4


Related Papers